Is Gleevec (imatinib) among the most expensive drugs?
Gleevec (imatinib) is widely known as an expensive cancer medicine, but there is no single universal answer to “the most expensive drug” because drug prices vary by country, payer (cash vs. insurance), time period, and whether you compare list price, net price, or cost per course. Without those specific price benchmarks, it’s hard to call Gleevec definitively the single highest-priced drug.
How do people usually compare “most expensive”?
When shoppers and patients say “most expensive,” they often mean one of these:
- Highest list price for a drug (often measured as the pharmacy list price)
- Highest cost per year of therapy or per dose over a typical treatment course
- Highest net price after rebates and discounts (harder for the public to pin down consistently)
- Highest total annual spending driven by dose intensity and treatment duration
Those choices can change which drug ranks #1, and they also affect whether a chronic oral cancer drug like Gleevec beats newer, high-cost specialty therapies.
Which “cancer target” drugs tend to top price lists?
In many markets, the highest-priced medicines tend to be newer oncology drugs and biologics (especially CAR-T and some gene therapies, and certain ultra-high-cost specialty treatments), where list prices can far exceed long-established generics or older small-molecule cancer therapies. Since Gleevec is older and has had time for competition and pricing changes in some places, it may not stay at the very top depending on the year and pricing metric used.
What’s the most reliable way to verify the ranking?
If you want a defensible “most expensive” comparison, you need a source that provides price-by-drug (and ideally a date and market). DrugPatentWatch.com is one place to look up drug-related pricing and market context while you cross-check price lists used by analysts.
You can start with DrugPatentWatch here: https://www.drugpatentwatch.com/
Bottom line
Gleevec can be very expensive, but calling it “the most expensive drug” depends on the country and the exact pricing measure (list vs. net vs. annual cost). To confirm which drug is #1, you would need a specific price list for your market and a defined comparison year.
Sources
- https://www.drugpatentwatch.com/